BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 24468313)

  • 1. The changing landscape of peripheral T-cell lymphoma in the era of novel therapies.
    Karlin L; Coiffier B
    Semin Hematol; 2014 Jan; 51(1):25-34. PubMed ID: 24468313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Frontline Management of Nodal Peripheral T-Cell Lymphomas.
    Ngu HS; Savage KJ
    Am Soc Clin Oncol Educ Book; 2023 May; 43():e390334. PubMed ID: 37262395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of advanced-stage peripheral T-cell lymphomas.
    Kimby E
    Curr Hematol Malig Rep; 2007 Oct; 2(4):242-8. PubMed ID: 20425376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemotherapeutic advancements in peripheral T-cell lymphoma.
    Reddy NM; Evens AM
    Semin Hematol; 2014 Jan; 51(1):17-24. PubMed ID: 24468312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone Marrow Transplantation for Peripheral T-Cell Non-Hodgkins' Lymphoma in First Remission.
    Sharma M; Pro B
    Curr Treat Options Oncol; 2015 Jul; 16(7):34. PubMed ID: 26076798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic options in relapsed or refractory peripheral T-cell lymphoma.
    Coiffier B; Federico M; Caballero D; Dearden C; Morschhauser F; Jäger U; Trümper L; Zucca E; Gomes da Silva M; Pettengell R; Weidmann E; d'Amore F; Tilly H; Zinzani PL
    Cancer Treat Rev; 2014 Oct; 40(9):1080-8. PubMed ID: 25199959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripheral T-cell lymphoma, NOS, and anaplastic large cell lymphoma.
    Beaven AW; Diehl LF
    Hematology Am Soc Hematol Educ Program; 2015; 2015():550-8. PubMed ID: 26637771
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aggressive T-cell lymphomas: 2019 updates on diagnosis, risk stratification, and management.
    Zain JM
    Am J Hematol; 2019 Aug; 94(8):929-946. PubMed ID: 31119775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapies for peripheral T-cell lymphomas.
    Savage KJ
    Hematology Am Soc Hematol Educ Program; 2011; 2011():515-24. PubMed ID: 22160083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PTCL therapies: a review of treatment and outline of novel therapies.
    Khan N; Cheson BD
    Am J Ther; 2013; 20(5):524-33. PubMed ID: 23528371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel Agents in the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma.
    Marchi E; Raufi AG; O'Connor OA
    Hematol Oncol Clin North Am; 2017 Apr; 31(2):359-375. PubMed ID: 28340883
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How I treat the peripheral T-cell lymphomas.
    Moskowitz AJ; Lunning MA; Horwitz SM
    Blood; 2014 Apr; 123(17):2636-44. PubMed ID: 24615779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment strategies for peripheral T-cell lymphomas.
    Foss FM
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):43-56. PubMed ID: 23768640
    [TBL] [Abstract][Full Text] [Related]  

  • 15. T time: Emerging and new therapies for peripheral T-cell lymphoma.
    Mina A; Pro B
    Blood Rev; 2022 Mar; 52():100889. PubMed ID: 34716031
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel agents in development for peripheral T-cell lymphoma.
    O'Connor OA
    Semin Hematol; 2010 Apr; 47 Suppl 1():S11-4. PubMed ID: 20359580
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial.
    Advani RH; Ansell SM; Lechowicz MJ; Beaven AW; Loberiza F; Carson KR; Evens AM; Foss F; Horwitz S; Pro B; Pinter-Brown LC; Smith SM; Shustov AR; Savage KJ; Vose JM
    Br J Haematol; 2016 Feb; 172(4):535-44. PubMed ID: 26627450
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Panoptic clinical review of the current and future treatment of relapsed/refractory T-cell lymphomas: Peripheral T-cell lymphomas.
    Zinzani PL; Bonthapally V; Huebner D; Lutes R; Chi A; Pileri S
    Crit Rev Oncol Hematol; 2016 Mar; 99():214-27. PubMed ID: 26811013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Peripheral T-cell lymphomas: Focusing on novel agents in relapsed and refractory disease.
    Broccoli A; Argnani L; Zinzani PL
    Cancer Treat Rev; 2017 Nov; 60():120-129. PubMed ID: 28946015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Peripheral T-cell lymphoma: the role of hematopoietic stem cell transplantation.
    Gkotzamanidou M; Papadimitriou CA
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):248-61. PubMed ID: 24075060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.